ALTIMMUNE, INC. (ALT) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 68.22M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 14.66M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -100.22M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $68.22M | (m) | $14.66M | $-100.22M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $66.80M | (m) | $15.44M | $-96.92M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $66.43M | $41.00K | $16.08M | $-94.49M | (m) | 162029.27% | 39209.76% | (m) | (m) |
| 2025-09-30 | $67.80M | $20.00K | $14.49M | $-90.46M | (m) | 339020.00% | 72445.00% | (m) | (m) |
| 2025-06-30 | $72.65M | $20.00K | $14.01M | $-94.37M | (m) | 363235.00% | 70065.00% | (m) | (m) |
| 2025-03-31 | $76.57M | $20.00K | $14.76M | $-98.19M | (m) | 382830.00% | 73790.00% | (m) | (m) |
| 2024-12-31 | $82.23M | $20.00K | $14.39M | $-103.17M | (m) | 411130.00% | 71965.00% | (m) | (m) |
| 2024-09-30 | $79.35M | $52.00K | $13.51M | $-111.93M | (m) | 152603.85% | 25976.92% | (m) | (m) |
| 2024-06-30 | $77.94M | $409.00K | $13.14M | $-109.70M | (m) | 19055.99% | 3212.71% | (m) | (m) |
| 2024-03-31 | $70.04M | $410.00K | $11.62M | $-100.96M | $34.00K | 17082.20% | 2832.93% | -2969.53× | Reported |
| 2023-12-31 | $65.80M | $426.00K | $10.64M | $-95.93M | $35.00K | 15445.77% | 2497.65% | -2740.83× | Reported |
| 2023-09-30 | $68.07M | $279.00K | $10.06M | $-85.40M | $-150.00K | 24397.49% | 3606.81% | (m) | Reported |
| 2023-06-30 | $69.94M | $-81.00K | $9.48M | $-87.61M | $-115.00K | -86349.38% | -11704.94% | (m) | Reported |
| 2023-03-31 | $72.68M | $-79.00K | $8.74M | $-90.00M | $-52.00K | -92003.80% | -11067.09% | (m) | Reported |
| 2022-12-31 | $70.54M | $-68.00K | $8.10M | $-87.74M | $8.00K | -103732.35% | -11913.24% | -10967.50× | Reported |
| 2022-09-30 | $71.54M | $3.32M | $7.53M | $-88.63M | $129.66K | 2155.36% | 226.79% | -683.59× | Reported |
| 2022-06-30 | $80.49M | $3.48M | $6.90M | $-97.08M | $98.66K | 2315.97% | 198.45% | -984.06× | Reported |
| 2022-03-31 | $77.77M | $3.60M | $6.33M | $-101.55M | $55.66K | 2157.59% | 175.73% | -1824.64× | Reported |
| 2021-12-31 | $74.54M | $4.41M | $5.52M | $-96.91M | $5.66K | 1690.14% | 125.13% | -17134.73× | Reported |
| 2021-09-30 | $63.31M | $3.45M | $4.91M | $-83.68M | $68.72K | 1837.42% | 142.52% | -1217.75× | Reported |
| 2021-06-30 | $51.14M | $6.23M | $4.73M | $-68.80M | $38.13K | 821.46% | 76.03% | -1804.57× | Reported |
| 2021-03-31 | $54.46M | $6.81M | $3.58M | $-62.35M | $19.21K | 799.79% | 52.56% | -3246.41× | Reported |
| 2020-12-31 | $49.77M | $8.19M | $2.58M | $-54.80M | $9.42K | 608.11% | 31.47% | -5816.66× | Reported |
| 2020-09-30 | $43.70M | $6.45M | $2.14M | $-48.36M | $7.47K | 677.67% | 33.26% | -6475.77× | Reported |
| 2020-06-30 | $35.38M | $4.15M | $1.11M | $-41.31M | $5.95K | 851.80% | 26.77% | -6944.06× | Reported |
| 2020-03-31 | $21.74M | $5.06M | $1.07M | $-26.44M | $3.39K | 429.68% | 21.18% | -7802.63× | Reported |
| 2019-12-31 | $17.77M | $5.80M | $1.26M | $-21.46M | $2.24K | 306.23% | 21.79% | -9565.48× | Reported |
| 2019-09-30 | $17.96M | $7.81M | $1.05M | $-44.50M | $129.60K | 229.80% | 13.49% | -343.36× | Reported |
| 2019-06-30 | $13.96M | $9.80M | $861.84K | $-37.28M | $295.79K | 142.34% | 8.79% | -126.05× | Reported |
| 2019-03-31 | $15.93M | $10.60M | $824.25K | $-39.17M | $296.96K | 150.34% | 7.78% | -131.90× | Reported |
| 2018-12-31 | $18.46M | $10.33M | $773.25K | $-42.83M | $297.09K | 178.68% | 7.48% | -144.18× | Reported |
| 2018-09-30 | $19.85M | $10.55M | $1.01M | $-28.05M | $171.77K | 188.17% | 9.58% | -163.31× | Reported |
| 2018-06-30 | $21.03M | $12.51M | $1.37M | $-54.95M | $7.17K | 168.13% | 10.94% | -7662.43× | Reported |
| 2018-03-31 | $21.37M | $13.13M | $1.46M | $-53.52M | $102.41K | 162.74% | 11.08% | -522.65× | Reported |
| 2017-12-31 | $18.41M | $10.74M | $1.44M | $-52.05M | $162.14K | 171.41% | 13.44% | -320.99× | Reported |
| 2017-09-30 | $13.94M | (m) | $2.79M | $-42.75M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $10.43M | (m) | $2.53M | $-16.59M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $4.53M | (m) | $2.12M | $-13.19M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $4.84M | (m) | $2.24M | $-11.26M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $4.58M | (m) | $2.08M | $-6.69M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $4.47M | (m) | $628.51K | $-4.36M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $4.55M | (m) | $595.31K | $-5.82M | $30.31K | (m) | (m) | -191.99× | Reported |
| 2015-12-31 | $5.13M | (m) | $613.02K | $-3.40M | $54.58K | (m) | (m) | -62.34× | Reported |
| 2015-09-30 | $5.75M | (m) | $909.93K | $-5.09M | $85.53K | (m) | (m) | -59.46× | Reported |
| 2015-06-30 | $6.36M | (m) | $1.10M | $-7.42M | $122.58K | (m) | (m) | -60.56× | Reported |
| 2015-03-31 | $7.51M | (m) | $1.33M | $-6.63M | $165.85K | (m) | (m) | -39.97× | Reported |
| 2014-12-31 | $9.32M | (m) | $1.66M | $-10.19M | $210.40K | (m) | (m) | -48.44× | Reported |
| 2014-09-30 | $11.63M | (m) | $1.58M | $-12.64M | $253.69K | (m) | (m) | -49.81× | Reported |
| 2014-06-30 | $12.45M | (m) | $1.60M | $-11.84M | $296.57K | (m) | (m) | -39.92× | Reported |
| 2014-03-31 | $13.48M | (m) | $1.56M | $-12.15M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $15.29M | (m) | $1.36M | $-10.84M | $369.28K | (m) | (m) | -29.35× | Reported |
| 2013-09-30 | $15.94M | (m) | $1.35M | $-7.20M | $405.29K | (m) | (m) | -17.76× | Reported |
| 2013-06-30 | $18.52M | (m) | $1.49M | $-5.79M | $428.00K | (m) | (m) | -13.53× | Reported |
| 2013-03-31 | $20.04M | (m) | $1.67M | $-5.77M | $439.32K | (m) | (m) | -13.13× | Reported |
| 2012-12-31 | $19.51M | (m) | $1.89M | $-6.27M | $342.56K | (m) | (m) | -18.29× | Reported |
| 2012-09-30 | $19.29M | (m) | $2.18M | $-5.92M | $240.94K | (m) | (m) | -24.58× | Reported |
| 2012-06-30 | $19.04M | (m) | $2.37M | $-7.15M | $138.35K | (m) | (m) | -51.71× | Reported |
| 2012-03-31 | $20.10M | (m) | $2.40M | $-8.78M | $42.17K | (m) | (m) | -208.14× | Reported |
| 2011-12-31 | $21.22M | $24.27M | $2.57M | $-11.73M | $54.57K | 87.45% | 10.57% | -214.86× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $20.88M | $20.99M | $2.51M | $-23.55M | $5.94M | 99.44% | 11.97% | -3.97× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |